Daniel James Hodson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel James Hodson has a total of 831 co-authors. Here are the top co-authors by number of shared publications:
- Louis M. Staudt
Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
62 shared publications - Galina Shevchenko
Center for Gene Therapy, City of Hope-Beckman Research Institute at the City of Hope, Duarte, CA 91010
60 shared publications - Stefania Pittaluga
Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA
59 shared publications - Thomas Oellerich
Goethe University Frankfurt, University Hospital, University Cancer Center (UCT)
59 shared publications - Clive S. D’santos
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom
58 shared publications - Evangelia K. Papachristou
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
58 shared publications
Latest Publications
- 12 November 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (20) , 2511-2527
CD70 overexpression at diagnosis predicts relapse and supports dual CD19-CD70 CAR T-cell therapy in follicular lymphoma
Although first-line immunotherapy achieves remission in most patients with follicular lymphoma (FL), improved biomarkers and therapeutic strategies are required to identify and manage those who relapse. We investigated the immune microenvironment at diagnosis in uniformly treated patients with FL with extended follow-up (>11 years), comparing patients with relapsed disease and those with relapse-free disease. Transcriptomic profiling revealed the enrichment of inflammatory response pathways in relapsed patients, including cytokine overexpression and upregulation of CD70, a molecule implicated in immune activation and inflammation. Multiplex immunofluorescence confirmed CD70 overexpression at diagnosis in tumor cells as well as in CD8+ and CD4+ T follicular helper cells, correlating with inferior progression-free survival. Functional studies demonstrated that CD70+ tumor cells were more proliferative and induced CD70 expression in T cells, suggesting a feed-forward loop sustaining immune activation. To target these cells and enhance current chimeric antigen receptor (CAR) T-cell approaches, we engineered dual CD19-CD70 CAR T cells by cotransducing the CD19 CAR T-cell product ARI-0001 with a CD27-based anti-CD70 CAR. Dual CAR T cells exhibited enhanced in vitro cytotoxicity against patient-derived spheroids of FL, diffuse large B-cell lymphoma, and mantle cell lymphoma. In FL xenograft models, dual CAR T-cell treatment achieved superior disease control compared to monotargeted CAR T cells, inducing complete tumor clearance in the spleen and bone marrow. Collectively, these findings provide a strong preclinical rationale for the clinical development of CD19-CD70 dual CAR T-cell therapy to improve outcomes in high-risk FL and potentially other B-cell non-Hodgkin lymphomas.
- 12 November 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (20) , 2511-2527
CD70 overexpression at diagnosis predicts relapse and supports dual CD19-CD70 CAR T-cell therapy in follicular lymphoma
Although first-line immunotherapy achieves remission in most patients with follicular lymphoma (FL), improved biomarkers and therapeutic strategies are required to identify and manage those who relapse. We investigated the immune microenvironment at diagnosis in uniformly treated patients with FL with extended follow-up (>11 years), comparing patients with relapsed disease and those with relapse-free disease. Transcriptomic profiling revealed the enrichment of inflammatory response pathways in relapsed patients, including cytokine overexpression and upregulation of CD70, a molecule implicated in immune activation and inflammation. Multiplex immunofluorescence confirmed CD70 overexpression at diagnosis in tumor cells as well as in CD8+ and CD4+ T follicular helper cells, correlating with inferior progression-free survival. Functional studies demonstrated that CD70+ tumor cells were more proliferative and induced CD70 expression in T cells, suggesting a feed-forward loop sustaining immune activation. To target these cells and enhance current chimeric antigen receptor (CAR) T-cell approaches, we engineered dual CD19-CD70 CAR T cells by cotransducing the CD19 CAR T-cell product ARI-0001 with a CD27-based anti-CD70 CAR. Dual CAR T cells exhibited enhanced in vitro cytotoxicity against patient-derived spheroids of FL, diffuse large B-cell lymphoma, and mantle cell lymphoma. In FL xenograft models, dual CAR T-cell treatment achieved superior disease control compared to monotargeted CAR T cells, inducing complete tumor clearance in the spleen and bone marrow. Collectively, these findings provide a strong preclinical rationale for the clinical development of CD19-CD70 dual CAR T-cell therapy to improve outcomes in high-risk FL and potentially other B-cell non-Hodgkin lymphomas.
- 3 September 2026
- Published by American Society of Hematology in Blood
Technical Considerations in the choice and use of ctDNA for Large B-cell lymphoma (LBCL)
Diffuse Large B-cell lymphoma is an aggressive lymphoma in which management is constrained by incomplete molecular characterization and the absence of sensitive markers of treatment response. Cell-free DNA offers a noninvasive approach for tumor genotyping and minimal residual disease monitoring. Nevertheless, technical challenges persist, including low cfDNA abundance and the discrimination of low allele fraction variants from background noise. Tumor-informed assays tracking multiple genetic markers substantially improve sensitivity of disease monitoring. Standardization and prospective validation will facilitate routine clinical implementation.
- 3 September 2026
- Published by American Society of Hematology in Blood
Technical Considerations in the choice and use of ctDNA for Large B-cell lymphoma (LBCL)
Diffuse Large B-cell lymphoma is an aggressive lymphoma in which management is constrained by incomplete molecular characterization and the absence of sensitive markers of treatment response. Cell-free DNA offers a noninvasive approach for tumor genotyping and minimal residual disease monitoring. Nevertheless, technical challenges persist, including low cfDNA abundance and the discrimination of low allele fraction variants from background noise. Tumor-informed assays tracking multiple genetic markers substantially improve sensitivity of disease monitoring. Standardization and prospective validation will facilitate routine clinical implementation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
CD79B Segregation Score and Pola-V CSS for Golgi glycosylation genes shows specific sugar regulators of surface CD79B and Pola-V sensitization
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
CD79B Segregation Score and Pola-V CSS for Golgi glycosylation genes shows specific sugar regulators of surface CD79B and Pola-V sensitization
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
KLHL6 loss does not score as a negative regulator of surface CD79B or Pola-V sensitivity in CRISPR screens of ABC DLBCL cell lines and KLHL6 loss does not sensitize to MMAE
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
KLHL6 loss does not score as a negative regulator of surface CD79B or Pola-V sensitivity in CRISPR screens of ABC DLBCL cell lines and KLHL6 loss does not sensitize to MMAE
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
CD79B is degraded in a lysosomal, not proteasomal manner
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
CD79B is degraded in a lysosomal, not proteasomal manner
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Knockout of Klhl6 in mouse germinal center B cells increases surface BCR expression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Knockout of Klhl6 in mouse germinal center B cells increases surface BCR expression
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Knockout of SLC35A1, SLC35A2, and ST6GAL1 decreases surface a2,6-linked sialic acid.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Knockout of SLC35A1, SLC35A2, and ST6GAL1 decreases surface a2,6-linked sialic acid.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Small-molecule sialyltransferase inhibition synergizes with Pola-V in ABC and GCB DLBCL
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Small-molecule sialyltransferase inhibition synergizes with Pola-V in ABC and GCB DLBCL
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma